top of page

Accreditation

Target Audience:

The initiative will target a total of 1,600 healthcare professionals, physicians, nurses, nurse practitioners, physician assistants, and pharmacists and provide the latest information on medical developments and implications for patient management in liver disease.

 

Program Overview:

The accredited 4th Annual Liver Update will deliver focused, educational updates highlighting clinically relevant advances in the management of patients with CLD. The update will be held in conjunction with the 2024 Liver Connect Conference on April 4-6, 2024, in Scottsdale, Arizona and will feature an interactive hybrid format to enhance the educational impact.

Educational Objectives:
Upon completion of this activity, participants should be able to:

  • Describe CLD management recommendations/guidelines for new treatments and describe current guidelines for the diagnosis and management of gastrointestinal disorders.

  • Utilize new therapies and employ an evidence-based approach to the management of gastrointestinal disorders to optimize treatment results for patients with CLD.

  • Identify new advances and assess their potential impact on clinical practice.

Physician Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and the Chronic Liver Disease Foundation (CLDF). Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation:
Purdue University College of Pharmacy designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Upon completing an evaluation, please note the maximum credit hours to be claimed for the following sessions: 

  • Liver Connect Plenary Sessions (no parallel session): maximum amount of credits = 9.0 AMA PRA Category 1 Credits™.

  • Liver Connect Plenary Sessions and HBV-ACT (parallel session): maximum amount of credits = 12.5 AMA PRA Category 1 Credits™.

  • Liver Connect Plenary Sessions and Pediatric Liver Disease MASLD Workshop (parallel session): maximum amount of credits = 11.0 AMA PRA Category 1 Credits™.

  • Pediatric Connect (if participating, add credits to one of the choices above): maximum amount of credits = 2.75 AMA PRA Category 1 Credits™.
     

Disclosure of Relevant Financial Relationships:

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

All relevant conflicts of interest have been mitigated prior to the start of the activity.

None of the planners, reviewers, CLDF staff, and Purdue University College of Pharmacy staff have relevant financial relationships with ineligible companies to disclose unless listed below.

 

Fee Information:

Click here to view the conference fees.

Jointly provided by Purdue University College of Pharmacy and the Chronic Liver Disease Foundation.

This activity is supported by an educational grant from Orphalan and Salix Pharmaceuticals.

Purdue Logo_2020.png
CLDF-logo_with space.png
bottom of page